Quantcast

Latest Valeant Pharmaceuticals International Inc. Stories

2014-09-15 16:29:11

LAVAL, Quebec, Sept. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX:VRX) today announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem all of the outstanding $500.0 million aggregate principal amount of its 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 (the "Notes") on October 15, 2014 and has mailed an irrevocable notice of redemption for the Notes. On September 15, 2014, a copy of the...

2014-09-08 16:25:58

Hosted Ribbon Cutting Ceremony for the New Bausch + Lomb ULTRA® Contact Lens Manufacturing Line and Solar Array Implementation LAVAL, Quebec, Sept. 8, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the company hosted a ribbon cutting ceremony for the new Bausch + Lomb ULTRA® contact lens manufacturing lines and solar array assembly at the company's Optics Center in Rochester, NY. The ceremony recognized the expansion...

2014-08-15 16:24:18

LAVAL, Quebec, Aug. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan, Inc. ("Allergan") (NYSE: AGN) to 5:00 p.m., New York City time, on December 31, 2014. The exchange offer was previously scheduled to expire at 5:00 p.m., New York City time today, Friday, August 15, 2014. All other terms and conditions of the exchange offer...

2014-08-11 20:24:49

QUEBEC, Aug. 11, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced that the Company has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Valeant's proposed acquisition of Allergan, Inc. (NYSE: AGN). The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). The effect of the second request is to...

2014-08-06 16:28:46

ISS Raises Significant Concerns about Corporate Governance Practices at Allergan LAVAL, Quebec and NEW YORK, Aug. 6, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX: VRX) and Pershing Square Capital Management, L.P. ("Pershing Square") today commented on Institutional Shareholder Services' ("ISS") recommendation in support of Pershing Square's effort to call a special meeting of Allergan shareholders. Pershing Square is seeking to call a special...

2014-08-01 16:23:51

Desperate Allergan Attempt to Interfere with the Special Meeting LAVAL, Quebec and NEW YORK, Aug. 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. today responded to the filing of a federal lawsuit by Allergan, Inc. (NYSE: AGN) in California. The complaint makes baseless claims about Valeant and Pershing Square regarding the tender offer rules. Allergan's true purpose in bringing the litigation is an attempt to...

2014-07-31 08:34:07

LAVAL, Quebec, July 31, 2014 /PRNewswire/ -- -- 2014 Second Quarter Total Revenue $2.0 billion; an increase of 86% over the prior year -- Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% -- 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, an increase of 43% -- 2014 Second Quarter GAAP Operating Cash Flow $376 million;...

2014-07-24 08:33:41

LAVAL, Quebec, July 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the Autorite des marches financiers ("AMF") regarding Allergan, Inc.'s (NYSE: AGN) apparent attempts to mislead investors and to negatively influence the market price of Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements...

2014-07-18 08:24:42

Bausch + Lomb's Organic Growth 12% for the Second Quarter of 2014, over 90% Due to Volume LAVAL, Quebec, July 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has filed an investor presentation with the Securities and Exchange Commission that will be used in meetings with Allergan's institutional investors and proxy advisors, the first of which is being held today, regarding calling a special meeting. The presentation includes a preview...

2014-07-17 08:29:09

VICTUS Platform Offers One of the Largest Arrays of FDA-Cleared Applications for Femto-Assisted Cataract and Refractive Surgery LAVAL, Quebec, July 17, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS(®) Femtosecond Laser Platform for laser-assisted lens fragmentation* during cataract...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related